The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | CB011: a novel genome-engineered BCMA-specific CAR-T cell therapy
In this video, Steven Kanner, PhD, Caribou Biosciences, Berkeley, CA, explains a novel BCMA-specific allogeneic chimeric antigen receptor T-cell (CAR-T) therapy known as CB-011, and the genome-editing technology behind this product. First, Dr Kanner discusses how CRISPR hybrid RNA-DNA (chRDNA), a highly specific form of genome editing, is implemented into allogeneic CAR-T and natural killer (NK) therapies to increase the persistence of these cells. Dr Kanner then provides more detail on the strategy behind CB-011, explaining how the knocking out of class I antigens on the CAR-T cells and insertion of a fusion protein prevents cytotoxic T-cells from reacting against CB-011, and NK cells from rejecting the graft. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
